Know Your Myeloma Therapy: REVLIMID with Dr. Craig Cole
Know Your Myeloma Therapy: REVLIMID with Dr. Craig Cole image
Apr 28, 2022 / 02:00PM - 03:00PM EDT
African American Myeloma Chapter

Event Description

Most myeloma patients are familiar with the drug Revlimid (lenalidomide). Not only is it used in the frontline setting, but also in relapsed refractory myeloma and as single agent maintenance for many. It is very well tolerated for most patients but not everyone is able to take it.

Join the African American Myeloma Community Chapter as they welcome Dr. Craig Emmit Cole to discuss Revlimid, its mechanism of action, side effect profile, who it might not work for, possible risk of secondary cancers, and what is in the works for a transdermal version of the drug.

Schedule & Agenda

person
Introduction
02:00PM
Valarie Traynham
Valarie introduces the agenda of the event and featured speaker Dr. Craig Cole.
person
Presentation
02:05PM
Dr. Craig Cole
Join the African American Myeloma Community Chapter as they welcomeDr. Cole discusses Revlimid, its mechanism of action, side effect profile, who it might not work for, possible risk of secondary cancers, and what is in the works for a transdermal version of the drug.
person
Questions and Answers
02:35PM
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Valarie Traynham
Valarie Traynham

“I became a Myeloma Coach after meeting many patients who did not have a peer mentor to ask questions and find relevant information about myeloma.”

Read Bio
The panelist Craig E. Cole, M.D.
Craig E. Cole, M.D.

Craig Emmitt Cole, M.D. is a board-certified Hematologist who received his Bachelor of Science degree in physiology at Michigan State University and the College of Lyman Briggs, in East Lansing Michigan. Dr. Cole went on to receive his doctoral degree at the Ohio State University College of Medicine in Columbus, Ohio. He completed his Internal Medicine Residency and Hematology/Oncology Fellowship at the University of Michigan Health System, Ann Arbor, Michigan. Dr. Cole subsequently had a post-fellowship laboratory research position at the Jerome Lipper Multiple Myeloma Center of Medicine at Dana-Farber Cancer Institute in Boston, Massachusetts. This opportunity then led to him becoming an attending hematologist at Gundersen Health System in La Crosse, Wisconsin for 9 years. There he was an instructor for both the medical and nursing schools of the western campus of the University of Wisconsin School of Medicine and Public Health. He also served as Affiliate Faculty Member of Graduate Community Health Programs and Assistant Professor (Adjunct) at the University of Wisconsin-La Crosse, Department of Health Professions. While in Wisconsin, his clinical research interest was in multiple myeloma, malignant hematology, clinical apheresis, and patient reported outcomes in hematology. He then returned to the University of Michigan Rogel Cancer Center in Ann Arbor, Michigan as an Assistant Professor in the Division of Hematology/Oncology with his primary clinical and research interest being in multiple myeloma. In May of 2019, he returned to Michigan State University College of Human Medicine at Breslin Cancer Center as the Director of Clinical Research in Hematology/ Oncology and Multiple Myeloma. Dr. Cole has been participated in over 50 clinical trials in Multiple Myeloma and Malignant Hematology. He is a member of the International Myeloma Working Group, International Myeloma Society and the American Society of Hematology; he has published in national journals and presented at the American Society of Hematology International Myeloma Workshop, and the American Society for Apheresis meetings. He has lectured across the United States to patients, researchers and clinical providers in multiple myeloma, plasma cell dyscrasias, and disparities in cancer care. He has won awards for his work in student and resident teaching, multiple myeloma research, and patient advocacy. Dr. Cole has always had a strong commitment to equity of cancer care, patient empowerment, and community education by working with several local and national patient advocacy associations to bring the good news of myeloma research to everyone.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811